Non-Superiority [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2022-07-26 17:04 (1032 d 03:09 ago) – Posting: # 23179
Views: 3,869

Hi Dennis,

❝ ❝ You hope that the complication rates in group A (with medicine) are lower than in group B (without medicine), right?


❝ However, we try to show the complication rates in group B (without medicine) are lower (or not worse or non-inferiority) than in group A (with medicine), …


Essentially you are trying to show that the medicine doesn’t perform better than placebo (assuming the study is double-blind). :-D:blind:

❝ … duo to the medicine is very expensive.


Likely you will face problems with the IEC/IRB:It is the job of the IEC/IRB to make a benefit/risk-assessment for the subjects in the study. To assess a potential socio-econommic advantage for the health system is not in the job description of the members.

❝ Is there any other probelm for the design?


IMHO, ethics.



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,681 registered users;
56 visitors (0 registered, 56 guests [including 32 identified bots]).
Forum time: 20:13 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5